Medicure Valuation

Is MCUJ.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MCUJ.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MCUJ.F ($0.68) is trading above our estimate of fair value ($0.12)

Significantly Below Fair Value: MCUJ.F is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MCUJ.F?

Key metric: As MCUJ.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MCUJ.F. This is calculated by dividing MCUJ.F's market cap by their current revenue.
What is MCUJ.F's PS Ratio?
PS Ratio	0.4x
Sales	CA$20.93m
Market Cap	CA$9.39m

MCUJ.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.2x
Enterprise Value/EBITDA	-4.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does MCUJ.F's PS Ratio compare to its peers?

The above table shows the PS ratio for MCUJ.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	18.8x
ABVC ABVC BioPharma	12.3x	n/a	US$6.6m
MYNZ Mainz Biomed	5.8x	81.8%	US$5.3m
SILO Silo Pharma	54.2x	n/a	US$3.9m
AQB AquaBounty Technologies	3.1x	11.9%	US$3.6m
MCUJ.F Medicure	0.4x	n/a	US$9.4m

Price-To-Sales vs Peers: MCUJ.F is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (18.8x).

Price to Sales Ratio vs Industry

How does MCUJ.F's PS Ratio compare vs other companies in the US Biotechs Industry?

129 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	9.4x	21.4%
MCUJ.F Medicure	0.4x	n/a	US$6.72m
GILD Gilead Sciences	4x	2.4%	US$112.40b
BIIB Biogen	2.4x	1.3%	US$23.01b

129 Companies		Estimated Growth	Market Cap
Industry Avg.	9.4x	28.3%
MCUJ.F Medicure	0.4x	n/a	US$6.72m

No more companies

Price-To-Sales vs Industry: MCUJ.F is good value based on its Price-To-Sales Ratio (0.4x) compared to the US Biotechs industry average (9.6x).

Price to Sales Ratio vs Fair Ratio

What is MCUJ.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MCUJ.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate MCUJ.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

5.3%

17.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$204.02

6.8%

-3.2%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$58.64

6.1%

14.8%